GWM
ARQT icon

GK Wealth Management’s Arcutis Biotherapeutics ARQT Stock Holding History

GK Wealth Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,984
Closed -$435K – 62
2025
Q4 		$435K Sell
14,984
-2,601
-15% -$66.6K 0.29% 87
2025
Q3 		$331K Sell
17,585
-1,216
-6% -$19.2K 0.24% 99
2025
Q2 		$264K Buy
18,801
+4,134
+28% +$58K 0.24% 108
2025
Q1 		$229K Buy
+14,667
New +$207K 0.26% 113

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GK Wealth Management's ARQT Position: Q1 2026 in Review

GK Wealth Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 14,984 shares — an estimated $435K sold.

GK Wealth Management first reported a position in ARQT in Q1 2025 and held it in 4 quarters. The position peaked at $435K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • GK Wealth Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • GK Wealth Management sold 14,984 Arcutis Biotherapeutics shares in Q1 2026, an estimated $435K.
  • GK Wealth Management first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 4 quarters.
  • GK Wealth Management's Arcutis Biotherapeutics position peaked at $435K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on GK Wealth Management's 13F filing for Q1 2026, filed 7 Apr 2026.